The role of G-CSF in zidovudine-induced leukopenia and granulocytopenia (G) in AIDS patients (pts): results of a pilot study (Meeting abstract).

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

The role of G-CSF in zidovudine-induced leukopenia and granulocytopenia (G) in AIDS patients (pts): results of a pilot study (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 12:A20 1993. Unique Identifier : AIDSLINE ICDB/93694420
Katz A; Levy GC; Albert Einstein Hosp., Sao Paulo, Brazil

Abstract: AIDS pts often develop leukopenia and G, either related to the HIV infection itself or associated with the use of myelosupressive drugs such as AZT, cytotoxic chemotherapy or DHPG. This common event may prevent the use of these agents or require its temporary or definitive discontinuation. This problem might become specially distressful in pts with neurologic manifestations of AIDS receiving AZT or AIDS pts requiring the use of cytotoxic chemotherapy for the treatment of an AIDS-related neoplasm. Given the fact that the G of AIDS pts is usually persistent, and that the chronic use of G-CSF might be required, it is not only important to design effective S of administration but also to try to use the minimum dose intensity (MDI) required to maintain its efficacy, for obvious economical reasons. From March 1991 to April 1992, we treated 12 adult AIDS pts with AZT-induced G (WBC less than 2500 cells/mm3 and absolute neutrophil count less than 1200 cells/mm3). Four pts had neurological manifestations of AIDS and 6 had cancer (lymphoma 2, KS 4). Pts initially received daily sc G-CSF at 4-5 mg/kg until adequate counts (AC) were achieved (WBC count greater than 5000/mm3 and ANC greater than 3000/mm3). WBC was always checked immediately before each dose of G-CSF. AC were usually achieved after 2 to 4 days of continuous therapy. Once AC were achieved we tried to determine the MDI required to maintain AC on each pt. We found that 11/12 pts G-CSF could be given 2 to 3x/wk, at doses ranging from 150 to 300 ug/day. The use of G-CSF enabled us to safely use AZT and chemotherapy in adequate doses and schedules.

Keywords: Acquired Immunodeficiency Syndrome/*DRUG THERAPY/IMMUNOLOGY Adult Agranulocytosis/*CHEMICALLY INDUCED/IMMUNOLOGY/THERAPY Dose-Response Relationship, Drug Drug Administration Schedule Granulocyte Colony-Stimulating Factor/*ADMINISTRATION & DOSAGE Human Leukocyte Count/DRUG EFFECTS Leukopenia/*CHEMICALLY INDUCED/IMMUNOLOGY/THERAPY Pilot Projects Zidovudine/ADMINISTRATION & DOSAGE/*ADVERSE EFFECTS ABSTRACT
931230
M93C0802

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .